Are there clinical trials of DSIP?

No established programme of registered interventional trials, and no regulator has reviewed it.

Which paper should I read first?

Kovalzon's 2006 review in the Journal of Neurochemistry, PMID 16539679. It is the clearest available account of what has and has not been established.

Does 519 papers mean DSIP is well established?

No. Publication volume reflects sustained interest in an unresolved question rather than accumulated confirmation of an answer.

DSIP (Delta Sleep-Inducing Peptide)

DSIP in the Published Literature

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

PubMed indexes roughly 519 DSIP records, spanning from the 1977 isolation to the present. Despite that volume the central claim remains unresolved, and the field's own 2006 review describes it as a riddle. Publication count here reflects sustained interest rather than accumulated confirmation.

Key facts

Indexed PubMed records: ~519
First publication: March 1977 (PNAS)
Sequence paper: 1978, Pflügers Arch
Key review: Kovalzon 2006, J Neurochem
Review's verdict: 'A still unresolved riddle'
Registered clinical trials: None established
Regulatory review: None

A large literature and a small conclusion

519 records is substantially more than Selank's 135 or Semax's 231, and comparable to well-studied research compounds. Yet the question that prompted the first paper — does this peptide have a role in sleep — has no settled answer. That combination is the most useful thing to know about the literature before reading any individual paper in it.

Why volume is not weight

Papers accumulate for many reasons. A tractable question with a clear answer generates a burst of work and then stops. An interesting question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. DSIP's publication profile looks much more like the second pattern, and Kovalzon's 2006 title states the field's assessment explicitly.

Research material referenced

DSIP 5mg — third-party HPLC tested

View — £13.99

The shape of the work

The literature spans the original isolation and sequencing, a large body of animal work examining sleep and other reported activities, and reviews periodically taking stock. What it does not contain is the gene, precursor and receptor work that would have converted the hypothesis into biology, and it contains no established programme of registered clinical trials.

The 1970s context

DSIP emerged during a period of intense interest in humoral sleep factors — the idea that sleep is driven by circulating substances that accumulate during waking. Several candidates were proposed in that era and most did not survive as sleep factors, though some found other roles. Reading DSIP as part of that cohort, rather than in isolation, makes its trajectory less surprising.

How to search it

PubMed indexes the field under 'delta sleep-inducing peptide'; the INN emideltide surfaces regulatory records the abbreviation misses. Filtering by publication type separates reviews from primary research, and checking the model organism is the fastest way to establish what kind of evidence a paper offers. For DSIP specifically, checking whether a paper administers the peptide or merely measures it is the most informative single question.

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light — the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Are there clinical trials of DSIP?: No established programme of registered interventional trials, and no regulator has reviewed it.
Which paper should I read first?: Kovalzon's 2006 review in the Journal of Neurochemistry, PMID 16539679. It is the clearest available account of what has and has not been established.
Does 519 papers mean DSIP is well established?: No. Publication volume reflects sustained interest in an unresolved question rather than accumulated confirmation of an answer.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum